Annual report pursuant to Section 13 and 15(d)

Stockholders??? Equity (Details Narrative)

v3.23.1
Stockholders’ Equity (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
May 31, 2022
Apr. 30, 2022
Mar. 31, 2022
Feb. 28, 2022
Jan. 31, 2022
Aug. 31, 2021
Jan. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Nov. 30, 2022
Aug. 31, 2022
Subsidiary, Sale of Stock [Line Items]                      
Common stock shares, outstanding               15,016,295 9,914,158    
Proceeds from Warrant Exercises               $ 4    
Stock-based compensation               $ 947 $ 1,505    
2015 Plan [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of additional shares authorized             1,000,000        
Common Stock [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Issuance of common stock, net, shares               1,151 2,775    
Common Stock [Member] | Common Stock To Maxim Group Llc [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of shares agreed to issue                   337,078  
Stock-based compensation               $ 300      
Common Stock [Member] | Services Agreement With Maxim Mdm Worldwide Solutions [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of shares agreed to issue                     50,000
Stock-based compensation               79,000      
Common Stock [Member] | Restricted stock agreement with Maxim Group, LLC [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of shares agreed to issue           50,000          
Stock-based compensation               $ 71,000      
Vesting period           12 months          
JT Pharmaceuticals [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Issuance of common stock, net, shares         51,021            
Milestone payment         $ 100,000            
Pre-Funded Warrants [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of warrants issued 1,289,796 1,300,000 974,242                
Proceeds from Warrant Exercises $ 1,290 $ 1,300 $ 1,000                
February 2022 Offerings [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Issuance of common stock, net, shares       1,100,000              
Proceeds from sale of common stock       $ 5,000              
February 2022 Offerings [Member] | Pre-Funded Warrants [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of warrants issued       2,274,242              
Exercise price of warrants, shares       $ 0.001              
February 2022 Offerings [Member] | Unregistered prefunded warrants [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of warrants issued       1,289,796              
Exercise price of warrants, shares       $ 0.001              
February 2022 Offerings [Member] | Unregistered five year and six month warrants [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Number of warrants issued       4,664,038              
Exercise price of warrants, shares       $ 1.14              
January 2021 Offering [Member]                      
Subsidiary, Sale of Stock [Line Items]                      
Issuance of common stock, net, shares             2,725,000        
Number of warrants issued             2,725,000        
Exercise price of warrants, shares             $ 3.55